Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypes.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
26 02 2020
Historique:
received: 05 07 2019
accepted: 28 01 2020
entrez: 28 2 2020
pubmed: 28 2 2020
medline: 24 4 2020
Statut: epublish

Résumé

Pogo transposable element derived with ZNF domain (POGZ) has been identified as one of the most recurrently de novo mutated genes in patients with neurodevelopmental disorders (NDDs), including autism spectrum disorder (ASD), intellectual disability and White-Sutton syndrome; however, the neurobiological basis behind these disorders remains unknown. Here, we show that POGZ regulates neuronal development and that ASD-related de novo mutations impair neuronal development in the developing mouse brain and induced pluripotent cell lines from an ASD patient. We also develop the first mouse model heterozygous for a de novo POGZ mutation identified in a patient with ASD, and we identify ASD-like abnormalities in the mice. Importantly, social deficits can be treated by compensatory inhibition of elevated cell excitability in the mice. Our results provide insight into how de novo mutations on high-confidence ASD genes lead to impaired mature cortical network function, which underlies the cellular pathogenesis of NDDs, including ASD.

Identifiants

pubmed: 32103003
doi: 10.1038/s41467-020-14697-z
pii: 10.1038/s41467-020-14697-z
pmc: PMC7044294
doi:

Substances chimiques

POGZ protein, human 0
Transposases EC 2.7.7.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

859

Références

de la Torre-Ubieta, L., Won, H., Stein, J. L. & Geschwind, D. H. Advancing the understanding of autism disease mechanisms through genetics. Nat. Med. 22, 345–361 (2016).
pubmed: 27050589 pmcid: 5072455
Courchesne, E. et al. The ASD Living Biology: from cell proliferation to clinical phenotype. Mol. Psychiatry 24, 88–107 (2018).
pubmed: 29934544 pmcid: 6309606
Xu, G., Strathearn, L., Liu, B. & Bao, W. Prevalence of autism spectrum disorder among US children and adolescents, 2014–2016. JAMA 319, 81–82 (2018).
pubmed: 29297068 pmcid: 5833544
Christensen, D. L. et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. Morbidity Mortal. Wkly. Rep. Surveill. Summ. (Wash., DC: 2002) 65, 1–23 (2018).
Tick, B., Bolton, P., Happe, F., Rutter, M. & Rijsdijk, F. Heritability of autism spectrum disorders: a meta-analysis of twin studies. J. Child Psychol. Psychiatry 57, 585–595 (2016).
pubmed: 26709141
Gaugler, T. et al. Most genetic risk for autism resides with common variation. Nat. Genet. 46, 881–885 (2014).
pubmed: 25038753 pmcid: 4137411
Abrahams, B. S. et al. SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs). Mol. Autism 4, 36 (2013).
pubmed: 24090431 pmcid: 3851189
Carter, M. T. & Scherer, S. W. Autism spectrum disorder in the genetics clinic: a review. Clin. Genet. 83, 399–407 (2013).
pubmed: 23425232
Tammimies, K. et al. Molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorder. JAMA 314, 895–903 (2015).
pubmed: 26325558
Turner, T. N. et al. Genomic patterns of de novo mutation in simplex autism. Cell 171, 710–722 (2017).
pubmed: 28965761 pmcid: 5679715
Janecka, M. et al. Advanced paternal age effects in neurodevelopmental disorders—review of potential underlying mechanisms. Transl. Psychiatry 7, e1019 (2017).
pubmed: 28140401 pmcid: 5299396
Deciphering Developmental Disorder Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature 542, 433–438 (2017).
Wilfert, A. B., Sulovari, A., Turner, T. N., Coe, B. P. & Eichler, E. E. Recurrent de novo mutations in neurodevelopmental disorders: properties and clinical implications. Genome Med. 9, 101 (2017).
pubmed: 29179772 pmcid: 5704398
De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209–215 (2014).
pubmed: 25363760 pmcid: 4402723
Hashimoto, R. et al. Whole-exome sequencing and neurite outgrowth analysis in autism spectrum disorder. J. Hum. Genet. 61, 199–206 (2016).
pubmed: 26582266
Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 515, 216–221 (2014).
pubmed: 25363768 pmcid: 4313871
Takata, A. et al. Integrative analyses of de novo mutations provide deeper biological insights into autism spectrum disorder. Cell Rep. 22, 734–747 (2018).
pubmed: 29346770
Li, J. et al. A comparative study of the genetic components of three subcategories of autism spectrum disorder. Mol. Psychiatry 24, 1720–1731 (2019).
pubmed: 29875476
Krumm, N. et al. Excess of rare, inherited truncating mutations in autism. Nat. Genet. 47, 582–588 (2015).
pubmed: 25961944 pmcid: 4449286
Sanders, S. J. et al. Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. Neuron 87, 1215–1233 (2015).
pubmed: 26402605 pmcid: 4624267
Gompers, A. L. et al. Germline Chd8 haploinsufficiency alters brain development in mouse. Nat. Neurosci. 20, 1062–1073 (2017).
pubmed: 28671691 pmcid: 6008102
Platt, R. J. et al. Chd8 mutation leads to autistic-like behaviors and impaired striatal circuits. Cell Rep. 19, 335–350 (2017).
pubmed: 28402856 pmcid: 5455342
Durak, O. et al. Chd8 mediates cortical neurogenesis via transcriptional regulation of cell cycle and Wnt signaling. Nat. Neurosci. 19, 1477–1488 (2016).
pubmed: 27694995 pmcid: 5386887
Katayama, Y. et al. CHD8 haploinsufficiency results in autistic-like phenotypes in mice. Nature 537, 675–679 (2016).
pubmed: 27602517 pmcid: 27602517
Jung, E. M. et al. Arid1b haploinsufficiency disrupts cortical interneuron development and mouse behavior. Nat. Neurosci. 20, 1694–1707 (2017).
pubmed: 29184203 pmcid: 5726525
Shibutani, M. et al. Arid1b haploinsufficiency causes abnormal brain gene expression and autism-related behaviors in mice. Int. J. Mol. Sci. 18, E1872 (2017).
pubmed: 28867767 pmcid: 28867767
Celen, C. et al. Arid1b haploinsufficient mice reveal neuropsychiatric phenotypes and reversible causes of growth impairment. eLife 6, e25730 (2017).
pubmed: 28695822 pmcid: 5515576
Dentici, M. L. et al. Expanding the phenotypic spectrum of truncating POGZ mutations: association with CNS malformations, skeletal abnormalities, and distinctive facial dysmorphism. Am. J. Med. Genet. A 173, 1965–1969 (2017).
pubmed: 28480548 pmcid: 28480548
Yuen, R. et al. Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. Nat. Neurosci. 20, 602–611 (2017).
pmcid: 5501701
White, J. et al. POGZ truncating alleles cause syndromic intellectual disability. Genome Med. 8, 3 (2016).
pubmed: 26739615 pmcid: 4702300
Stessman, H. A. F. et al. Disruption of POGZ is associated with intellectual disability and autism spectrum disorders. Am. J. Hum. Genet. 98, 541–552 (2016).
pubmed: 26942287 pmcid: 4890241
Tan, B. et al. A novel de novo POGZ mutation in a patient with intellectual disability. J. Hum. Genet. 61, 357–359 (2016).
pubmed: 26763879
Fukai, R. et al. A case of autism spectrum disorder arising from a de novo missense mutation in POGZ. J. Hum. Genet. 60, 277–279 (2015).
pubmed: 25694107
Ye, Y. et al. De novo POGZ mutations are associated with neurodevelopmental disorders and microcephaly. Cold Spring Harb. Mol. Case Stud. 1, a000455 (2015).
pubmed: 27148570 pmcid: 4850885
Ostapcuk, V. et al. Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes. Nature 557, 739–743 (2018).
pubmed: 29795351
Gunther, M., Laithier, M. & Brison, O. A set of proteins interacting with transcription factor Sp1 identified in a two-hybrid screening. Mol. Cell. Biochem. 210, 131–142 (2000).
pubmed: 10976766
Gudmundsdottir, B. et al. POGZ is required for silencing mouse embryonic beta-like hemoglobin and human fetal hemoglobin expression. Cell Rep. 23, 3236–3248 (2018).
pubmed: 29898395
Vermeulen, M. et al. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell 142, 967–980 (2010).
pubmed: 20850016
Lui, J. H., Hansen, D. V. & Kriegstein, A. R. Development and evolution of the human neocortex. Cell 146, 18–36 (2011).
pubmed: 21729779 pmcid: 3610574
Rusanescu, G. & Mao, J. Notch3 is necessary for neuronal differentiation and maturation in the adult spinal cord. J. Cell. Mol. Med. 18, 2103–2116 (2014).
pubmed: 25164209 pmcid: 4244024
Nelson, S. B. & Valakh, V. Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. Neuron 87, 684–698 (2015).
pubmed: 26291155 pmcid: 4567857
Paterson, C. & Law, A. J. Toward better strategies for understanding disrupted cortical excitatory/inhibitory balance in schizophrenia. Biol. Psychiatry 83, 632–634 (2018).
pubmed: 29559094
Eguchi, M. & Yamaguchi, S. In vivo and in vitro visualization of gene expression dynamics over extensive areas of the brain. Neuroimage 44, 1274–1283 (2009).
pubmed: 19059347
Seiriki, K. et al. High-speed and scalable whole-brain imaging in rodents and primates. Neuron 94, 1085–1100 e1086 (2017).
pubmed: 28641108
Seiriki, K. et al. Whole-brain block-face serial microscopy tomography at subcellular resolution using FAST. Nat. Protoc. 14, 1509–1529 (2019).
pubmed: 30962606
Mundy, P. A review of joint attention and social-cognitive brain systems in typical development and autism spectrum disorder. Eur. J. Neurosci. 47, 497–514 (2018).
pubmed: 28922520
Waye, M. M. Y. & Cheng, H. Y. Genetics and epigenetics of autism: a review. Psychiatry Clin. Neurosci. 72, 228–244 (2018).
pubmed: 28941239
Gilbert, J. & Man, H. Y. Fundamental elements in autism: from neurogenesis and neurite growth to synaptic plasticity. Front. Cell. Neurosci. 11, 359 (2017).
pubmed: 29209173 pmcid: 5701944
Nithianantharajah, J. & Grant, S. G. Cognitive components in mice and humans: combining genetics and touchscreens for medical translation. Neurobiol. Learn. Mem. 105, 13–19 (2013).
pubmed: 23796634
Hiroi, N. Critical reappraisal of mechanistic links of copy number variants to dimensional constructs of neuropsychiatric disorders in mouse models. Psychiatry Clin. Neurosci. 72, 301–321 (2018).
pubmed: 29369447 pmcid: 5935536
O’Tuathaigh, C. M. P., Moran, P. M., Zhen, X. C. & Waddington, J. L. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. Br. J. Pharmacol. 174, 3173–3190 (2017).
pubmed: 28667666 pmcid: 5595756
Sundelin, H. E. et al. Autism and epilepsy: a population-based nationwide cohort study. Neurology 87, 192–197 (2016).
pubmed: 27306624 pmcid: 4940061
Tuchman, R. & Rapin, I. Epilepsy in autism. Lancet Neurol. 1, 352–358 (2002).
pubmed: 12849396 pmcid: 12849396
Selimbeyoglu, A. et al. Modulation of prefrontal cortex excitation/inhibition balance rescues social behavior in CNTNAP2-deficient mice. Sci. Transl. Med. 9, eaah6733 (2017).
pubmed: 28768803 pmcid: 5723386
Yizhar, O. et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 477, 171–178 (2011).
pubmed: 21796121 pmcid: 4155501
Nakazawa, T. et al. Emerging roles of ARHGAP33 in intracellular trafficking of TrkB and pathophysiology of neuropsychiatric disorders. Nat. Commun. 7, 10594 (2016).
pubmed: 26839058 pmcid: 4742909
Okamoto, M. et al. DBZ regulates cortical cell positioning and neurite development by sustaining the anterograde transport of Lis1 and DISC1 through control of Ndel1 dual-phosphorylation. J. Neurosci. 35, 2942–2958 (2015).
pubmed: 25698733 pmcid: 6605587
American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn (DSM-IV. American Psychiatric Association, Washington, DC, 1994).
Yamada, A. et al. Emotional distress and its correlates among parents of children with pervasive developmental disorders. Psychiatry Clin. Neurosci. 61, 651–657 (2007).
pubmed: 18081627
Wakabayashi, A., Tojo, Y., Baron-Cohen, S. & Wheelwright, S. [The Autism-Spectrum Quotient (AQ) Japanese version: evidence from high-functioning clinical group and normal adults]. Shinrigaku kenkyu : Jpn. J. Psychol. 75, 78–84 (2004).
CommitteeJW-IP. Japanese Wechsler Intelligence Scale for Children. 3rd edn. (Nihon Bunka Kagakusha, Tokyo, 1998).
Nakazawa, T. et al. Differential gene expression profiles in neurons generated from lymphoblastoid B-cell line-derived iPS cells from monozygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine. Schizophr. Res. 181, 75–82 (2017).
pubmed: 28277309
Ayabe, S., Nakashima, K. & Yoshiki, A. Off- and on-target effects of genome editing in mouse embryos. J. Reprod. Dev. 65, 1–5 (2018).
pubmed: 30518723 pmcid: 6379761
Yoshimi, K. et al. ssODN-mediated knock-in with CRISPR-Cas for large genomic regions in zygotes. Nat. Commun. 7, 10431 (2016).
pubmed: 26786405 pmcid: 4736110
Hwang, W. Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 31, 227–229 (2013).
pubmed: 23360964 pmcid: 3686313
Pietras, A., von Stedingk, K., Lindgren, D., Pahlman, S. & Axelson, H. JAG2 induction in hypoxic tumor cells alters Notch signaling and enhances endothelial cell tube formation. Mol. Cancer Res. 9, 626–636 (2011).
pubmed: 21402725 pmcid: 21402725
Esteves de Lima, J., Bonnin, M. A., Birchmeier, C. & Duprez, D. Muscle contraction is required to maintain the pool of muscle progenitors via YAP and NOTCH during fetal myogenesis. eLife 5, e15593 (2016).
pubmed: 27554485 pmcid: 5030091
Kim, K. et al. Autophosphorylation of F-actin binding domain of CaMKIIbeta is required for fear learning. Neurobiol. Learn. Mem. 157, 86–95 (2018).
pubmed: 30528771 pmcid: 30528771
Scattoni, M. L., Gandhy, S. U., Ricceri, L. & Crawley, J. N. Unusual repertoire of vocalizations in the BTBR T+tf/J mouse model of autism. PLoS One 3, e3067 (2008).
pubmed: 18728777 pmcid: 2516927
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405 (2015).
pubmed: 25741868 pmcid: 4544753

Auteurs

Kensuke Matsumura (K)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.
Interdisciplinary Program for Biomedical Sciences, Institute for Transdisciplinary Graduate Degree Programs, Osaka University, Suita, Osaka, 565-0871, Japan.
Research Fellowships for Young Scientists of the Japan Society for the Promotion of Science, Chiyoda-ku, Tokyo, 102-0083, Japan.

Kaoru Seiriki (K)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.
Interdisciplinary Program for Biomedical Sciences, Institute for Transdisciplinary Graduate Degree Programs, Osaka University, Suita, Osaka, 565-0871, Japan.

Shota Okada (S)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Masashi Nagase (M)

Institute of Clinical Medicine and Research, Jikei University School of Medicine, Kashiwa, Chiba, 277-8567, Japan.

Shinya Ayabe (S)

Experimental Animal Division, RIKEN BioResource Research Center, Tsukuba, Ibaraki, 305-0074, Japan.

Ikuko Yamada (I)

Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center, Tsukuba, Ibaraki, 305-0074, Japan.

Tamio Furuse (T)

Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center, Tsukuba, Ibaraki, 305-0074, Japan.

Hirotoshi Shibuya (H)

Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center, Tsukuba, Ibaraki, 305-0074, Japan.

Yuka Yasuda (Y)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8553, Japan.
Life Grow Brilliant Clinic, Osaka, Osaka, 530-0012, Japan.

Hidenaga Yamamori (H)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8553, Japan.
Japan Community Health care Organization Osaka Hospital, Osaka, Osaka, 553-0003, Japan.

Michiko Fujimoto (M)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8553, Japan.
Department of Psychiatry, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan.

Kazuki Nagayasu (K)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Kana Yamamoto (K)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Kohei Kitagawa (K)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Hiroki Miura (H)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Nanaka Gotoda-Nishimura (N)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Hisato Igarashi (H)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Misuzu Hayashida (M)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Masayuki Baba (M)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Momoka Kondo (M)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Shigeru Hasebe (S)

Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, 565-0871, Japan.

Kosei Ueshima (K)

Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, 565-0871, Japan.

Atsushi Kasai (A)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Yukio Ago (Y)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.
Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Atsuko Hayata-Takano (A)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.
Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Suita, Osaka, 565-0871, Japan.

Norihito Shintani (N)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.

Tokuichi Iguchi (T)

Department of Anatomy and Neuroscience, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan.

Makoto Sato (M)

Department of Anatomy and Neuroscience, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan.
United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Suita, Osaka, 565-0871, Japan.
Research Center for Child Mental Development, University of Fukui, Fukui, Fukui, 910-1193, Japan.

Shun Yamaguchi (S)

Department of Morphological Neuroscience, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
Center for Highly Advanced Integration of Nano and Life Sciences, Gifu University, Gifu, 501-1194, Japan.

Masaru Tamura (M)

Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center, Tsukuba, Ibaraki, 305-0074, Japan.

Shigeharu Wakana (S)

Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center, Tsukuba, Ibaraki, 305-0074, Japan.
Department of Gerontology, Institute of Biomedical Research and Innovation, Kobe, Hyogo, 650-0047, Japan.

Atsushi Yoshiki (A)

Experimental Animal Division, RIKEN BioResource Research Center, Tsukuba, Ibaraki, 305-0074, Japan.

Ayako M Watabe (AM)

Institute of Clinical Medicine and Research, Jikei University School of Medicine, Kashiwa, Chiba, 277-8567, Japan.

Hideyuki Okano (H)

Department of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, 160-8582, Japan.

Kazuhiro Takuma (K)

Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, 565-0871, Japan.
Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Suita, Osaka, 565-0871, Japan.

Ryota Hashimoto (R)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8553, Japan.
Osaka University, Suita, Osaka, 565-0871, Japan.

Hitoshi Hashimoto (H)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp.
Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp.
Division of Bioscience, Institute for Datability Science, Osaka University, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp.
Transdimensional Life Imaging Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp.
Department of Molecular Pharmaceutical Science, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp.

Takanobu Nakazawa (T)

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan. takanobunakazawa-tky@umin.ac.jp.
Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, 565-0871, Japan. takanobunakazawa-tky@umin.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH